454 related articles for article (PubMed ID: 20305604)
1. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
[TBL] [Abstract][Full Text] [Related]
2. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
Khaldi S; Kornreich C; Choubani Z; Gourevitch R
Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
[TBL] [Abstract][Full Text] [Related]
3. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
4. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation.
Ochi S; Kawasoe K; Abe M; Fukuhara R; Sonobe K; Kawabe K; Ueno S
Gen Hosp Psychiatry; 2011; 33(6):640.e1-2. PubMed ID: 21749835
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report.
Kato D; Kawanishi C; Kishida I; Furuno T; Matsumura T; Hasegawa H; Suzuki K; Hirayasu Y
Psychiatry Clin Neurosci; 2005 Aug; 59(4):504-7. PubMed ID: 16048458
[TBL] [Abstract][Full Text] [Related]
6. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
7. Neuroleptic malignant syndrome in a patient with succinic semialdehyde dehydrogenase deficiency.
Neu P; Seyfert S; Brockmöller J; Dettling M; Marx P
Pharmacopsychiatry; 2002 Jan; 35(1):26-8. PubMed ID: 11819156
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.
Aklillu E; Kalow W; Endrenyi L; Harper P; Miura J; Ozdemir V
Pharmacogenet Genomics; 2007 Nov; 17(11):989-93. PubMed ID: 18075468
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
[TBL] [Abstract][Full Text] [Related]
10. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
11. Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding.
Mihara K; Kondo T; Higuchi H; Takahashi H; Yoshida K; Shimizu T; Kaneko S
Am J Med Genet; 2002 Aug; 114(6):693-5. PubMed ID: 12210290
[TBL] [Abstract][Full Text] [Related]
12. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
[TBL] [Abstract][Full Text] [Related]
13. [Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs].
Sénéchal A; Landry P; Deschamps R; Lessard M
Encephale; 2002; 28(6 Pt 1):567-9. PubMed ID: 12506270
[TBL] [Abstract][Full Text] [Related]
14. [Clinical pharmacogenetics in the treatment of schizophrenia].
Saito M; Yasui-Furukori N; Kaneko S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
[TBL] [Abstract][Full Text] [Related]
15. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].
Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S
Encephale; 2000; 26(1):62-7. PubMed ID: 10875063
[TBL] [Abstract][Full Text] [Related]
16. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
17. The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
Roke Y; van Harten PN; Franke B; Galesloot TE; Boot AM; Buitelaar JK
Pharmacogenet Genomics; 2013 Sep; 23(9):487-93. PubMed ID: 23851570
[TBL] [Abstract][Full Text] [Related]
18. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.
Yamanouchi Y; Iwata N; Suzuki T; Kitajima T; Ikeda M; Ozaki N
Pharmacogenomics J; 2003; 3(6):356-61. PubMed ID: 14610521
[TBL] [Abstract][Full Text] [Related]
19. Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction.
Normann C; Brandt C; Berger M; Walden J
Pharmacopsychiatry; 1998 Sep; 31(5):201-4. PubMed ID: 9832353
[TBL] [Abstract][Full Text] [Related]
20. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
